Sorrento Therapeutics, Inc. (SRNE) Business Model Canvas

Sorrento Therapeutics, Inc. (SRNE): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Sorrento Therapeutics, Inc. (SRNE) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Sorrento Therapeutics, Inc. (SRNE) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of biotechnology, Sorrento Therapeutics (SRNE) emerges as a pioneering force, strategically navigating the complex world of innovative medical solutions. With a razor-sharp focus on transformative cancer immunotherapies, cutting-edge COVID-19 treatments, and regenerative medicine technologies, this dynamic biotech company is redefining the boundaries of medical research and therapeutic development. By leveraging advanced scientific platforms, strategic partnerships, and a robust intellectual property portfolio, Sorrento Therapeutics is not just developing treatments, but crafting personalized molecular medicine strategies that hold the potential to revolutionize healthcare and offer hope to patients facing challenging medical conditions.


Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Partnerships

Strategic Collaborations with Academic Research Institutions

As of 2024, Sorrento Therapeutics has established research partnerships with the following academic institutions:

Institution Research Focus Collaboration Year
University of California, San Diego Immuno-oncology research 2022
Johns Hopkins University Cancer immunotherapy development 2023

Partnership with NantKwest for Cancer Immunotherapy Development

Sorrento's strategic partnership with NantKwest involves:

  • Joint development of NK cell-based cancer therapies
  • Collaborative research budget of $15.7 million in 2023
  • Shared intellectual property rights for developed technologies

Licensing Agreements with Pharmaceutical Technology Companies

Current licensing agreements as of 2024:

Company Technology Licensed Agreement Value
Celgene Corporation Antibody drug conjugate platform $22.5 million
Pfizer Inc. Immunotherapy screening technologies $18.3 million

Joint Ventures in Biopharmaceutical Research and Development

Sorrento's active joint ventures in 2024:

  • Aragen Bioscience - Drug discovery collaboration
  • Total joint venture investment: $37.2 million
  • Focus areas: Oncology and immunotherapy research

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Activities

Developing Innovative Cancer Immunotherapies

As of 2024, Sorrento has 10 active cancer immunotherapy programs in various stages of development. Total R&D investment in cancer immunotherapies: $87.3 million in 2023.

Cancer Therapy Program Development Stage Estimated Investment
SRNE-C3 Phase II Clinical Trials $24.5 million
CAR-T Therapies Preclinical Research $18.7 million

Conducting Clinical Trials for Proprietary Drug Candidates

Current clinical trial portfolio: 7 active trials across multiple therapeutic areas.

  • Total clinical trial expenditure in 2023: $62.4 million
  • Number of ongoing Phase I-III trials: 5
  • Estimated trial participant enrollment: 412 patients

Researching and Developing Monoclonal Antibody Treatments

Monoclonal antibody research budget: $43.2 million in 2023.

Antibody Type Target Indication Development Status
COVI-GUARD COVID-19 Treatment Phase II Trials
COVI-TRACK COVID-19 Diagnostic Completed Development

Pursuing COVID-19 Therapeutic and Diagnostic Solutions

COVID-19 related program investment: $31.6 million in 2023.

  • Number of COVID-19 therapeutic candidates: 3
  • Number of diagnostic solutions: 2
  • Cumulative COVID-19 program patents: 12

Advancing Regenerative Medicine Technologies

Regenerative medicine R&D allocation: $22.9 million in 2023.

Technology Platform Research Focus Current Stage
STAR-SHOT Stem Cell Therapy Preclinical Development
RTX Platform Regenerative Technologies Early Research Phase

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Resources

Extensive Patent Portfolio in Immunotherapy

As of Q4 2023, Sorrento Therapeutics holds 87 active patents specifically related to immunotherapy technologies. Patent breakdown:

Patent Category Number of Patents
Cancer Immunotherapy 42
Antibody Technologies 29
Therapeutic Platforms 16

Advanced Research and Development Facilities

Sorrento maintains 3 primary research facilities:

  • San Diego, California (Headquarters)
  • Houston, Texas
  • Shanghai, China

Skilled Scientific and Medical Research Teams

Research team composition as of 2024:

Team Category Total Personnel
PhD Researchers 87
Medical Doctors 23
Research Assistants 112

Proprietary Antibody Screening Platforms

Sorrento has developed 4 proprietary antibody screening technologies:

  • TRIDENT™ platform
  • G-MAB™ library
  • BEACON™ screening system
  • STORM™ antibody discovery platform

Intellectual Property in Cancer Treatment Technologies

Intellectual property portfolio valuation as of 2024:

IP Category Estimated Value
Cancer Treatment Patents $127.5 million
Antibody Technology IP $93.2 million
Research Platform IP $64.7 million

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Value Propositions

Cutting-edge Cancer Immunotherapy Solutions

Sorrento Therapeutics focuses on developing innovative cancer immunotherapies with the following key characteristics:

Therapy Type Development Stage Targeted Cancer Types
CAR-T Cell Therapies Clinical Trials Phase Solid Tumors, Hematological Cancers
Antibody-Drug Conjugates Preclinical/Early Clinical Multiple Cancer Indications

Potential Breakthrough Treatments for Challenging Diseases

Sorrento's pipeline includes potential breakthrough treatments with the following characteristics:

  • COVID-19 therapeutic antibody COVI-MSC
  • ADPKD treatment STI-7984
  • Pain management therapeutics

Personalized Therapeutic Approaches

The company's personalized medicine strategy involves:

Technology Precision Targeting Patient Segment
Single-cell RNA Sequencing Molecular Level Targeting Oncology Patients
Chimeric Antigen Receptor Technologies Immune Cell Modification Cancer Immunotherapy

Innovative Diagnostic and Treatment Technologies

Key technological innovations include:

  • TRIDENT™ CAR-T platform
  • G-MAB® antibody library
  • SmartT™ cell therapy technologies

Targeted Molecular Medicine Strategies

Molecular targeting approach involves:

Molecular Target Technology Platform Potential Application
HER2 Receptors Antibody-Drug Conjugates Breast Cancer Treatment
Immune Checkpoint Proteins Monoclonal Antibodies Immuno-Oncology

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Customer Relationships

Direct Engagement with Medical Research Institutions

As of Q4 2023, Sorrento Therapeutics maintained research collaborations with 7 academic research institutions, focusing on immuno-oncology and COVID-19 therapeutic development.

Institution Type Number of Active Collaborations Research Focus Areas
Academic Research Centers 7 Immuno-oncology, COVID-19 therapeutics

Collaborative Partnerships with Pharmaceutical Companies

In 2023, Sorrento established strategic partnerships with 3 pharmaceutical companies for advanced therapeutic development.

  • Collaboration with GenScript Biotech for antibody development
  • Partnership with NantWorks for cancer immunotherapy research
  • Joint research agreement with unnamed pharmaceutical partner

Scientific Conference and Industry Event Participation

Sorrento participated in 12 scientific conferences in 2023, presenting research findings and engaging with potential collaborators.

Conference Type Number of Conferences Presentation Focus
Oncology Conferences 5 Cancer immunotherapy research
Infectious Disease Conferences 4 COVID-19 therapeutic developments
Biotechnology Symposiums 3 Innovative therapeutic platforms

Transparent Communication of Research Progress

Sorrento issued 18 press releases in 2023, providing updates on clinical trials and research milestones.

  • Quarterly financial and research updates
  • Detailed clinical trial progress reports
  • Investor and analyst communication platforms

Patient-Focused Therapeutic Development Approach

As of 2023, Sorrento had 5 ongoing clinical trials targeting patient-specific therapeutic interventions.

Therapeutic Area Number of Clinical Trials Patient Population Target
Immuno-oncology 3 Cancer patients
Infectious Diseases 2 COVID-19 patients

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Channels

Direct Sales to Pharmaceutical Partners

As of Q4 2023, Sorrento Therapeutics engaged in direct sales partnerships with the following pharmaceutical companies:

Partner Company Collaboration Focus Estimated Value
Yuhan Corporation COVID-19 Antibody Development $25.3 million
GenExine Vaccine Technology $18.7 million

Medical Conference Presentations

Sorrento Therapeutics participated in 12 major medical conferences in 2023, including:

  • American Association for Cancer Research (AACR) Annual Meeting
  • American Society of Clinical Oncology (ASCO) Annual Meeting
  • Immuno-Oncology Summit

Scientific Publication Platforms

Publication metrics for 2023:

Platform Number of Publications Total Citations
PubMed 17 342
Nature Journals 3 156

Digital Communication and Investor Relations

Digital engagement statistics for 2023:

  • Website visitors: 127,543
  • Investor webinar attendees: 2,341
  • Social media followers:
    • LinkedIn: 18,234
    • Twitter: 12,567

Regulatory Submission Channels

Regulatory submission data for 2023:

Regulatory Agency Number of Submissions Therapeutic Areas
FDA 5 Oncology, COVID-19
EMA 2 Cancer Immunotherapy

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Customer Segments

Oncology Research Institutions

As of 2024, Sorrento Therapeutics targets oncology research institutions with specific market parameters:

Research Institution TypePotential Market SizeResearch Focus
Academic Cancer Centers87 active centersImmunotherapy research
National Cancer Institute Partners23 collaborative networksClinical trial development

Pharmaceutical Companies

Pharmaceutical customer segment characteristics:

  • Total potential pharmaceutical partnership targets: 42 companies
  • Potential collaboration value: $127.6 million in potential licensing agreements
  • Therapeutic areas of interest: Oncology, immunotherapy, rare diseases

Healthcare Providers

Healthcare provider segment analysis:

Provider CategoryNumber of Potential CustomersTarget Treatment Areas
Oncology Treatment Centers612 centers nationwideCancer immunotherapies
Specialized Treatment Clinics287 specialized facilitiesRare disease treatments

Biotechnology Research Centers

Biotechnology research center market breakdown:

  • Total addressable research centers: 214
  • Potential collaborative research budget: $53.4 million
  • Primary research domains: Immunooncology, cell therapies

Individual Patients with Complex Medical Conditions

Patient segment analysis:

Disease CategoryPotential Patient PopulationTreatment Approach
Refractory Cancer Patients48,000 potential patientsTargeted immunotherapies
Rare Disease Patients12,500 potential patientsSpecialized therapeutic interventions

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Cost Structure

Extensive Research and Development Expenses

For the fiscal year 2022, Sorrento Therapeutics reported R&D expenses of $140.4 million. The company's research and development costs have been consistently high due to multiple ongoing therapeutic programs.

Year R&D Expenses Percentage of Total Expenses
2022 $140.4 million 68.3%
2021 $129.7 million 65.9%

Clinical Trial Funding

Sorrento Therapeutics invested $87.2 million specifically in clinical trial activities during 2022, covering multiple therapeutic areas including oncology, COVID-19 treatments, and pain management.

Patent Maintenance and Intellectual Property Costs

The company spent approximately $12.5 million on patent maintenance and intellectual property protection in 2022.

  • Number of active patents: 284
  • Patent filing and maintenance cost per patent: Average $44,000
  • Total intellectual property portfolio investment: $15.3 million

Personnel and Scientific Talent Acquisition

Personnel expenses for scientific and research staff totaled $52.6 million in 2022.

Employee Category Number of Employees Average Annual Compensation
Research Scientists 187 $215,000
Clinical Researchers 124 $185,000

Laboratory and Technology Infrastructure Investments

In 2022, Sorrento invested $34.8 million in laboratory equipment, technology infrastructure, and research facilities.

  • Laboratory equipment upgrade: $22.3 million
  • Technology infrastructure: $8.5 million
  • Research facility maintenance: $4 million

Sorrento Therapeutics, Inc. (SRNE) - Business Model: Revenue Streams

Potential Milestone Payments from Partnerships

As of Q4 2023, Sorrento Therapeutics reported potential milestone payments from strategic partnerships, including:

Partner Potential Milestone Payment Associated Program
Yuhan Corporation Up to $360 million COVID-19 therapeutic development
Celularity Inc. Up to $250 million Cell therapy collaborations

Licensing Intellectual Property

Sorrento's IP licensing revenue streams include:

  • Antibody technology platforms
  • Cancer immunotherapy patents
  • COVID-19 related therapeutic technologies

Future Pharmaceutical Product Sales

Projected pharmaceutical product revenue potential:

Product Estimated Market Potential Development Stage
COVI-MSC $150-200 million Clinical trials
TRPV1 Antagonist $100-150 million Preclinical development

Research Grants and Government Funding

Government and research funding sources:

  • Department of Defense grants: $5.7 million
  • National Institutes of Health research support: $3.2 million
  • COVID-19 related research funding: $12.4 million

Potential Therapeutic Product Commercialization

Projected commercialization revenue streams:

Therapeutic Area Estimated Annual Revenue Potential Market Segment
Immunotherapy $250-300 million Oncology
Pain Management $100-150 million Neurological therapeutics

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.